| 65186 | |
| Mechanical damage to the nervous system of mammals sometimes results in irreversible functional deficits. Most functional deficits associated with trauma to both the Peripheral Nervous System (PNS) and Central Nervous System (CNS) result from damage to the nerve fiber or axon, blocking the flow of nerve impulse traffic along the nerve fiber. Spinal cord injury is a compression injury to the cord where the injured region of anatomically intact nerve fibers does not function. In particular, this local region (usually less than 1 vertebral segment in extent) does not conduct nerve impulses through the region of damage. 4-Aminopyridine (4-AP) has shown promise in restoring nerve function in paralyzed persons; however, clinically meaningful recoveries of function only occur in about 30 percent of the treated population. For the balance of those receiving treatment, recoveries are associated with numerous unwanted side effects, such as dizziness, loss of balance, and seizure. Researchers at Purdue University have developed analogues of 4-AP, which provide longer lasting effects at a lower concentration with fewer side effects than comparable treatments with 4-AP. The compounds, upon in vivo administration, reduced the effect of traumatic CNS tissue injury by the restoration of nerve impulse conduction through nerve tissue lesions. Advantages: -Analogue of known pharmaceutical -Restores nerve impulse and function in spinal cord injury -Longer lasting than current standard, with lower dose and fewer side effects Potential Applications: -Medical/Healthcare -Pharmaceuticals |
|
|
|
|
Sep 9, 2010
CIP-Patent
United States
8,729,107
May 20, 2014
(None)
Provisional-Patent
United States
(None)
(None)
(None)
PCT-Patent
WO
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
